Skip to main content
    C

    Cocrystal Pharma Inc (COCP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.98
    -0.00 (-0.24%)

    Market Cap: $18.88M

    Last updated: Nov 17, 2026 at 10:48 AM ET

    Cocrystal Pharma Inc (COCP) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Cocrystal Pharma reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$8.83M, operating cash flow was -$8.19M and free cash flow was -$8.20M. The quarter ended Sep 30, 2026 had revenue of $105.00K and net income of -$3.44M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $9.02M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$2.01M-69.3%100.0%-476.0%-479.0%
    Dec 2019$6.56MN/A100.0%-737.4%-733.8%
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$0$0$2.01M$6.56M$0$0$0
    Gross profit$0$0$0$0$0$2.01M$6.56M$0$0$0
    Research and development$5.05M$12.54M$15.17M$12.39M$8.79M$6.03M$4.00M$4.67M$5.82M$101.68M
    Operating income-$9.02M-$17.88M-$18.56M-$38.83M-$14.22M-$9.59M-$48.41M-$62.92M-$8.26M-$105.82M
    Net income-$8.83M-$17.50M-$17.98M-$38.84M-$14.19M-$9.65M-$48.17M-$49.05M-$613.00K-$74.87M
    EBITDA-$8.89MN/A-$18.43M-$38.65M-$13.80M-$9.30M-$47.90M-$62.63M-$7.38M-$104.19M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$105.00K$105.00K$225.00K$0$0$0$0$136.00K$0$0$0$144.00K
    Gross profit$105.00K$105.00K$225.00K$1.39M$0$0$0-$28.00K$0$0$0-$4.27M
    Operating income-$3.49M-$3.18M-$2.36M-$2.48M-$2.09M-$2.11M-$2.34M-$3.23M-$5.04M-$5.45M-$4.16M-$4.67M
    Net income-$3.44M-$3.16M-$2.30M-$2.43M-$2.05M-$2.06M-$2.30M-$3.27M-$4.94M-$5.34M-$3.96M-$4.46M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $334.00K by $6.69M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$9.71M$13.46M$31.26M$40.84M$79.39M$54.24M$28.53M$68.56M$121.43M$124.88M
    Current assets$8.13M$11.58M$29.09M$40.18M$59.32M$34.02M$8.28M$2.94M$2.18M$5.47M
    Cash and equivalents$7.03M$9.86M$26.35M$37.14M$58.70M$33.01M$7.42M$2.72M$748.00K$3.60M
    Total liabilities$3.38M$3.93M$4.88M$1.27M$1.84M$1.74M$2.82M$1.67M$16.03M$22.56M
    Short-term debt$334.00K$301.00K$240.00K$240.00K$236.00K$217.00K$280.00K$428.00K$0$1.48M
    Long-term debtN/AN/AN/AN/AN/AN/AN/AN/A$1.01M$0
    Shareholder equity$6.33M$9.52M$26.38M$39.57M$77.55M$52.51M$25.71M$66.89M$105.40M$102.32M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$6.77M$4.65M$7.43M$9.71M$10.45M$8.51M$10.66M$13.46M$16.23M$21.57M$26.55M$31.26M
    Total liabilities$4.10M$3.60M$3.31M$3.38M$2.78M$3.17M$3.35M$3.93M$3.53M$4.18M$3.96M$4.88M
    Cash and equivalents$4.87M$2.17M$4.68M$7.03M$7.73M$4.77M$6.92M$9.86M$13.02M$18.14M$21.84M$26.35M
    Shareholder equity$2.67M$1.04M$4.12M$6.33M$7.67M$5.33M$7.30M$9.52M$12.70M$17.39M$22.59M$26.38M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$8.19M-$16.48M-$14.67M-$21.43M-$12.72M-$9.83M-$1.56M-$8.29M-$6.90M-$14.65M
    Capital expenditures$12.00K$8.00K$118.00K$74.00K$52.00K$240.00K$145.00K$28.00K$40.00K$51.00K
    Free cash flow-$8.20M-$16.49M-$14.78M-$21.51M-$12.77M-$10.07M-$1.71M-$8.32M-$6.94M-$14.71M
    Investing cash flow-$12.00K-$8.00K-$118.00K-$74.00K-$52.00K-$240.00K-$145.00K$1.37M-$40.00K$3.00K
    Financing cash flow$5.37M$0$3.99M-$27.00K$38.47M$35.66M$6.42M$8.89M$4.08M$9.02M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.30M-$2.52M-$2.34M-$1.74M-$1.36M-$2.15M-$2.94M-$3.16M-$5.12M-$3.70M-$4.50M-$3.33M
    Capital expendituresN/AN/A$0$0$12.00K$0$0N/AN/AN/A$8.00K$59.00K
    Free cash flowN/AN/A-$2.34M-$1.74M-$1.37M-$2.15M-$2.94MN/AN/AN/A-$4.51M-$3.38M
    Last 12 quarters

    Frequently Asked Questions About COCP

    What is Cocrystal Pharma's annual revenue?

    Cocrystal Pharma reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Cocrystal Pharma profitable?

    No. Cocrystal Pharma reported net income of -$8.83M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does COCP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$8.19M minus capital expenditures of $12.00K produced free cash flow of -$8.20M.

    How much debt does Cocrystal Pharma have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $334.00K and cash and equivalents of $7.03M.